Welcome to our dedicated page for Y-Mabs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (YMAB) is a commercial-stage biopharmaceutical leader pioneering antibody-based therapies and radioimmunotherapy for pediatric and adult cancers. This page provides investors and medical professionals with comprehensive access to Y-mAbs' official news, including FDA regulatory updates, clinical trial results, and strategic partnership announcements.
As the developer of DANYELZA – an FDA-approved treatment for high-risk neuroblastoma – Y-mAbs demonstrates ongoing innovation through its SADA PRIT platform and bispecific antibody research. Our curated news collection enables stakeholders to track the company's progress in advancing precision oncology treatments while maintaining compliance with rigorous clinical standards.
Key updates include press releases on product commercialization milestones, peer-reviewed study publications, and developments in the company's pipeline targeting GD2-expressing tumors. All content is sourced directly from Y-mAbs Therapeutics and verified financial disclosures to ensure reliability.
Bookmark this page for real-time updates on YMAB's scientific advancements and market-moving developments. Investors can leverage this resource to monitor the company's progress in bringing novel radioimmunotherapies through clinical trials to commercialization.
Y-mAbs Therapeutics (YMAB) announced a compelling clinical update on DANYELZA® (naxitamab-gqgk) for refractory/relapsed high-risk neuroblastoma at the ESMO Immuno-Oncology Virtual Congress 2020. Study 201 showed an overall response rate (ORR) of 68%, with 59% complete responses. The treatment was primarily outpatient, demonstrating a 98% adherence rate and median infusion time of 37 minutes. DANYELZA, recently approved by the FDA, indicates significant potential in addressing unmet medical needs among difficult-to-treat patients.
Y-mAbs Therapeutics (Nasdaq: YMAB) will host a virtual R&D day on December 16, 2020, from 12 PM to 2 PM ET. Key Opinion Leaders, including Dr. Shakeel Modak from Memorial Sloan Kettering, will present topics on DANYELZA® (naxitamab-gqgk) and its combination with chemotherapy, along with updates on other studies related to osteosarcoma and DIPG. Management will detail advancements regarding their bispecific antibody, nivatrotamab, and additional products. Participants can register for the event online.
Y-mAbs Therapeutics (Nasdaq: YMAB) has partnered with Takeda Israel to establish an exclusive license and distribution agreement for DANYELZA and omburtamab in Israel. DANYELZA, which received FDA approval on November 25, 2020, treats relapsed/refractory high-risk neuroblastoma. Meanwhile, Y-mAbs plans to resubmit the BLA for omburtamab by early 2021. This agreement will facilitate access to these critical treatments for pediatric patients in Israel and surrounding regions, addressing unmet medical needs.
Y-mAbs Therapeutics announced FDA approval for DANYELZA (naxitamab-gqgk) 40mg/10ml, indicated for treating high-risk neuroblastoma in patients aged one and older. DANYELZA, combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), targets GD2, a ganglioside in neuroectoderm-derived tumors. This accelerated approval requires further clinical trials to confirm benefits. DANYELZA is expected in U.S. markets soon, supported by two pivotal studies showing manageable adverse events, enhancing Y-mAbs' oncology product pipeline.
Y-mAbs Therapeutics announced a clinical update on its treatment, omburtamab, for diffuse intrinsic pontine glioma (DIPG) during the SNO Virtual Annual Meeting. Data from a Phase 1 study indicated that repeated convection enhanced delivery (CED) infusions are feasible in pediatric patients. The study involved seven patients receiving multiple infusions without negatively impacting procedural aspects. Y-mAbs plans a multicenter Phase 2 trial aimed at improving outcomes for DIPG patients.
Y-mAbs Therapeutics reported a net loss of $32.8 million or ($0.82) per share for Q3 2020, compared to a $23.9 million loss in Q3 2019. Research and development expenses rose to $21.0 million, while general and administrative costs increased to $11.6 million.
Despite the financial losses, Y-mAbs is progressing with its pipeline, including a planned resubmission of the omburtamab BLA and advancements in nivatrotamab, which received Orphan Drug and Rare Pediatric Disease designations from the FDA.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) will report its financial results for Q3 2020 on November 5, 2020, after U.S. market close. A conference call will follow on November 6, 2020, at 9 a.m. ET, featuring Thomas Gad, Dr. Claus Moller, and Bo Kruse. Y-mAbs focuses on developing antibody-based therapies for cancer, with key candidates naxitamab and omburtamab targeting GD2 and B7-H3 tumors, respectively. The press release includes forward-looking statements regarding the company's business model, clinical trials, and potential risks related to financial conditions and product development.
Y-mAbs Therapeutics (Nasdaq: YMAB) announced FDA clearance for its Investigational New Drug (IND) application for 177Lu-omburtamab-DTPA. This treatment targets B7-H3 positive CNS and Leptomeningeal Metastasis in adult patients. The company plans to initiate a Phase 1/2 clinical trial in Q4 2020, leveraging experience from treating adults with 131I-omburtamab. Y-mAbs aims to address unmet medical needs in brain metastasis and expand its clinical reach.
Y-mAbs Therapeutics (YYMB) announced significant clinical updates on its therapies naxitamab and omburtamab at the SIOP Virtual Annual Congress. Naxitamab demonstrated a 68% overall response rate, with 59% achieving complete responses in a pivotal study of 22 patients. Meanwhile, omburtamab showed a promising 87% overall survival rate at 12 months in a study of 17 patients, compared to 30% in a historical control. The FDA has set a PDUFA date for naxitamab on November 30, 2020, indicating potential market entry for these novel cancer treatments.
Y-mAbs Therapeutics has received FDA clearance for its Investigational New Drug application for 177Lu-omburtamab-DTPA, aimed at treating medulloblastoma, a common childhood brain cancer. This product utilizes a radiolabeled antibody and is scheduled for a Phase 1/2 clinical trial targeting pediatric patients later in 2020. The company plans to also initiate a separate trial for adults with B7-H3 positive CNS/LM cancers. The omburtamab antibody was developed by Memorial Sloan Kettering, which has financial interests in Y-mAbs.